Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer Journal Article


Authors: Meirelles, G. S. P.; Schoder, H.; Ravizzini, G. C.; Gonen, M.; Fox, J. J.; Humm, J.; Morris, M. J.; Scher, H. I.; Larson, S. M.
Article Title: Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer
Abstract: Purpose: To compare the diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) and bone scans (BS) in the assessment of osseous lesions in patients with progressing prostate cancer. Experimental Design: In a prospective imaging trial, 43 patients underwent FDG-PET and BS prior to experimental therapies. Bone scan index (BSI) and standardized uptake value (SUV) on FDG-PET were recorded. Patients were followed until death (n = 36) or at least 5 years (n = 7). Imaging findings were correlated with survival. Results: Osseous lesions were detected in 39 patients on BS and 32 on FDG-PET (P = 0.01). Follow-up was available for 105 FDG-positive lesions, and 84 (80%) became positive on subsequent BS. Prognosis correlated inversely with SUV (median survival 14.4 versus 32.8 months if SUVmax > 6.10 versus ≤ 6.10; P = 0.002) and BSI (14.7 versus 28.2 months if BSI > 1.27 versus < 1.27; P = 0.004). Only SUV was an independent factor in multivariate analysis. Conclusion: This study of progressive prostate cancer confirms earlier work that BSI is a strong prognostic factor. Most FDG-only lesions at baseline become detectable on follow-up BS, suggesting their strong clinical relevance. FDG SUV is an independent prognostic factor and provides complementary prognostic information. ©2010 AACR.
Keywords: adult; cancer survival; aged; major clinical study; cancer growth; positron emission tomography; follow up; technetium 99m; prostate cancer; imaging system; bone lesion; diagnostic value; fluorodeoxyglucose f 18; intermethod comparison; bone scintiscanning
Journal Title: Clinical Cancer Research
Volume: 16
Issue: 24
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2010-12-15
Start Page: 6093
End Page: 6099
Language: English
DOI: 10.1158/1078-0432.ccr-10-1357
PROVIDER: scopus
PUBMED: 20975102
PMCID: PMC3402086
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Josef J Fox
    44 Fox
  2. Michael Morris
    274 Morris
  3. Mithat Gonen
    701 Gonen
  4. Heiko Schoder
    285 Schoder
  5. John Laurence Humm
    339 Humm
  6. Steven M Larson
    765 Larson
  7. Howard Scher
    817 Scher